Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study
Monica Grafals, Brian Smith, Naoka Murakami, Agnes Trabucco, Katherine Hamill, Erick Marangos, Hannah Gilligan, Elizabeth A Pomfret, James J Pomposelli, Mary A Simpson, Jamil Azzi, Nader Najafian, Leonardo V Riella, Monica Grafals, Brian Smith, Naoka Murakami, Agnes Trabucco, Katherine Hamill, Erick Marangos, Hannah Gilligan, Elizabeth A Pomfret, James J Pomposelli, Mary A Simpson, Jamil Azzi, Nader Najafian, Leonardo V Riella
Abstract
Rabbit antithymocyte globulin (ATG) is commonly used as an induction therapy in renal transplant recipients, but the ideal dosage in tacrolimus-based early steroid withdrawal protocols has not been established. The purpose of this pilot study was to determine the immunophenotyping and efficacy of lower dose ATG in low immunological-risk kidney transplant recipients. In this prospective study, 45 patients were randomized (1∶1) to our standard dose ATG (total dose 3.75 mg/kg)(sATG) vs. lower dose 2.25 mg/kg (lowATG). All patients underwent early steroid withdrawal within 7 days. The primary end point was biopsy-proven acute rejection at 12 months. Prospective immunophenotyping of freshly isolated PBMCs was performed at baseline, 3, 6, 12 months post-transplant. The rate of acute rejection was 17% and 10% in the sATG and lowATG, respectively. Effector memory T cells, Tregs and recent thymic emigrants T cells had similar kinetics post-transplant in both groups. No statistically significant differences were found in graft survival, patient survival or infections between the two groups, though there was a non-significant increase in leukopenia (43%v s. 30%), CMV (8% vs. 0) and BK (4% vs. 0) infections in sATG group vs. lowATG. In sum, in low immunological risk kidney recipients undergoing steroid withdrawal, low dose ATG seems to be efficacious in preventing acute rejection and depleting T cells with potentially lower infectious complications. A larger study is warranted to confirm these findings.
Trial registration: ClinicalTrials.gov NCT00548405.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715–2729.
- Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, et al. (2013) OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 13 Suppl 1: 11–46.
- Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, et al. (2006) Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 6: 1111–1131.
- Kirk AD (2006) Induction immunosuppression. Transplantation 82: 593–602.
- Thiyagarajan U, Ponnuswamy A, Bagul A (2013) Thymoglobulin and its use in renal transplantation: a review. American journal of nephrology 37: 586–601.
- Meier-Kriesche HU, Arndorfer JA, Kaplan B (2002) Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 13: 769–772.
- Opelz G, Naujokat C, Daniel V, Terness P, Dohler B (2006) Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81: 1227–1233.
- Thibaudin D, Alamartine E, Mariat C, Absi L, Berthoux F (2005) Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 80: 1514–1517.
- Brennan D, Daller J, Lake K, Cibrik D, Del Castillo D, et al. (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. The New England journal of medicine 355: 1967–1977.
- Goggins W, Pascual M, Powelson J, Magee C, Tolkoff-Rubin N, et al. (2003) A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 76: 798–802.
- Hardinger K, Rasu R, Skelton R, Miller B, Brennan D (2010) Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? Journal of transplantation 2010: 957549.
- Karen LH, Mark AS, Brent M, Jeffrey AL, Surendra S, et al.. (2004) Five-Year Follow Up of Thymoglobulin Versus ATGAM Induction in Adult Renal Transplantation. Transplantation 78..
- Lancaster GA, Dodd S, Williamson PR (2004) Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 10: 307–312.
- D'Addio F, Boenisch O, Magee C, Yeung M, Yuan X, et al.. (2013) Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. PloS one 8..
- Krystufkova E, Sekerkova A, Striz I, Brabcova I, Girmanova E, et al. (2012) Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant 27: 2576–2582.
- Zheng XX, Sanchez-Fueyo A, Domenig C, Strom TB (2003) The balance of deletion and regulation in allograft tolerance. Immunol Rev 196: 75–84.
- Fink PJ (2013) The biology of recent thymic emigrants. Annu Rev Immunol 31: 31–50.
- Hardinger K, Brennan D, Klein C (2013) Selection of induction therapy in kidney transplantation. Transplant international: official journal of the European Society for Organ Transplantation 26: 662–672.
- Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, et al. (1999) A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67: 1011–1018.
- Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, et al. (2008) A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8: 307–316.
- Gaber AO, Matas AJ, Henry ML, Brennan DC, Stevens RB, et al. (2012) Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation 94: 331–337.
- Rizzari MD, Suszynski TM, Gillingham KJ, Dunn TB, Ibrahim HN, et al. (2012) Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol 7: 494–503.
- Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, et al. (2006) Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 19: 629–635.
- Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, et al. (2008) A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 248: 564–577.
- Hardinger K, Rhee S, Buchanan P, Koch M, Miller B, et al. (2008) A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 86: 947–952.
- Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, et al. (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76: 120–129.
- Todeschini M, Cortinovis M, Perico N, Poli F, Innocente A, et al. (2013) In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol 191: 2818–2828.
- Farney AC, Doares W, Rogers J, Singh R, Hartmann E, et al. (2009) A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 88: 810–819.
- Hanaway M, Woodle E, Mulgaonkar S, Peddi V, Kaufman D, et al. (2011) Alemtuzumab induction in renal transplantation. The New England journal of medicine 364: 1909–1919.
- Gurkan S, Luan Y, Dhillon N, Allam S, Montague T, et al. (2010) Immune reconstitution following rabbit antithymocyte globulin. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 10: 2132–2141.
- Tchao N, Turka L (2012) Lymphodepletion and homeostatic proliferation: implications for transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 12: 1079–1090.
Source: PubMed